Acadia Pharmaceuticals develops treatments focused on neuropsychiatric disorders, aiming to improve the lives of those affected by these conditions. With over 30 years in the healthcare sector, the company holds a pioneering position, having introduced the first FDA-approved medication for hallucinations and delusions associated with Parkinson's Disease psychosis, as well as the first drug approved for Rett syndrome. Acadia's ongoing research targets various conditions, including Alzheimer's disease psychosis and Prader-Willi syndrome, while emphasizing a commitment to scientific innovation and patient-centered care. By fostering a culture of collaboration and integrity, Acadia strives to bring vital solutions to individuals in need and to contribute positively to the broader healthcare landscape.